Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2005-05-01
2008-12-16
Campell, Bruce (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C424S149100, C530S350000
Reexamination Certificate
active
07465537
ABSTRACT:
The inventors have discovered that an ATPase-deficient dominant-negative mutant NS3 protein of hepatitis C virus inhibits activity of the wild-type NS3 protein and inhibits replication of hepatitis C virus (HCV). The solved crystal structure of a multi-enzyme NS3 complex on a DNA substrate is also provided. The inventors have tested a peptide matching the sequence of a portion of NS3 that interacts with another NS3 molecule for inhibiting HCV replication. The peptide inhibits HCV replication. Accordingly, the invention provides a method of inhibiting HCV replication in cells infected with HCV involving transforming the cells with a vector expressing a dominant-negative mutant NS3 gene. The invention also provides a method of inhibiting HCV replication in cells infected with HCV involving administering to the cells a dominant-negative mutant NS3 protein. The invention also provides peptides and agents that inhibit HCV replication and methods of identifying agents that inhibit HCV replication.
REFERENCES:
patent: 5331573 (1994-07-01), Balaji et al.
patent: 5500807 (1996-03-01), Lavin et al.
patent: 7208309 (2007-04-01), Kukolj et al.
patent: 7241796 (2007-07-01), Farmer et al.
patent: WO 01/21189 (2001-03-01), None
Lamarre et al. An NS3 protease inhibitor with antivirial effects in humans infected with hepatitis C virus, Nature 2003, vol. 426, p. 186-189, 314.
Blanchard, E., Brand, D., Trassard, S., Goudeau, A., and Roingeard, P. (2002) Hepatitis C virus-like particle morphogenesis.J. Virol. 76, 4073-4079.
Blight, KJ, Kolykhalov AA, Rice CM (2000) Efficient initiation of HCV RNA replication in cell culture.Science290: 1972-1974.
Bohm, H-J (1992) The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors.J. Comp. Aid. Molec. Design6: 61-78.
Cho, HS, Ha NC, Kang LW, Chung KM, Back SH, Jang SK, Oh BH (1998) Crystal structure of RNA helicase from genotype 1b hepatitis C virus. A feasible mechanism of unwinding duplex RNA.J. Biol Chem273: 15045-15052.
Cho, Y. G., Yang, S. H., and Sung, Y. C. (1998) In vivo assay for hepatitis C viral serine proteiase activity using a secreted protein.J. Virol. Methods72, 109-115.
Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., and Houghton, M. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.Science244, 359-362.
Cristiano, R.J. et al. (1993) Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex.Proc. Nat'l. Acad. Sci. USA 90, 11548-11552.
Frick, DN, Rypma RS, Lam AM, Gu B (2004) The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently.J. Biol Chem279: 1269-1280.
Gallinari, P, Brennan D, Nardi C, Brunetti M, Tomei L, Steinkuhler C, De Francesco R (1998) Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus.J. Virol72: 6758-6769.
Goodford, PJ (1985) A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules.J. Med. Chem.28: 849-857.
Goodsell, DS and Olsen AJ (1990) Automated Docking of Substrates to Proteins by Simulated Annealing.Proteins: Structure. Function and Genetics8: 195-202.
Goregaoker, S. P. and Culver, J. N. (2003) Oligomerization and activity of the helicase domain of the tobacco mosaic virus 126- and 183-kilodalton replicase proteins.J. Virol.77, 3549-3556.
Ha, T, Rasnik I, Cheng W, Babcock HP, Gauss GH, Lohman TM, Chu S (2002) Initiation and re-intiation of DNA unwinding by theEscherichia coliRep helicase.Nature419: 638-41.
He, Y., Yan, W., Coito, C., Li, Y., Gale, M., Jr., and Katze, M. G. (2003) The regulation of hepatitis C virus (HCV) internal ribsome-entry site-mediated translation by HCV replicons and nonstructural proteins.J. Gen. Virol. 84, 535-543.
He, T-C, Zhou S, Da Costa LT, Yu J, Kinzler KW, and Vogelstein B (1998) A simplified system for generating recombinant adenovirus.Proc. Natl. Acad. Sci. USA95: 2509-14.
Huang, L., EV Sineva, MRS Hargittai, SD Sharma, M Suthar, KD Raney, CE Cameron (2004) Purification and characterization of hepatitis C virus non-structural protein 5A expressed inEscherichia coli. Prot. Exp. Purif. 37:144-153.
Khu, Y. L., Koh, E., Lim, S. P., Tan, Y. H., Brenner, S., Lim, S. G., Hong, W. J., and Goh, P. Y. (2001) Mutations that affect dimer formation and helicase activity of the hepatitis C virus helicase.J. Virol. 75, 205-214.
Kim, DW, Gwack Y, Han JH, Choe J (1995) C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity.Biochem Biophys Res Commun215: 160-166.
Kim, JL, Morgenstern KA, Griffith JP, Dwyer MD, Thomson JA, Murcko MA, Lin C, Caron PR (1998) Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding.Structure6: 89-100.
Krieger, N., Lohmann, V., and Bartenschlager, R. (2001) Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations.J. Virol. 75, 4614-4624.
Kuntz, ID (1992) Structure-based strategies for drug design and discovery.Science257: 1078-1082.
Kuntz, ID et al. (1982) A Geometric Approach to Macromolecule-Ligand Interactions.J. Mol. Biol. 161: 269-288.
Levin, MK, Wang YH, Patel SS (2004) The functional interaction of the hepatitis C virus helicase molecules is responsible for unwinding processivity.J Biol Chem279: 26005-26012.
Levin, MK, Patel SS (2002) Helicase from hepatitis C virus, energetics of DNA binding.J Biol Chem277: 29377-29385.
Levin, M. K. and Patel, S. S. (1999) The helicase from hepatitis C virus is active as an oligomer.J. Biol. Chem. 274, 31839-31846.
Lin, C, Thomson JA, Rice CM (1995) A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro.J. Virol69: 4373-4380.
Locatelli, GA, Spadari S, Maga G (2002) Hepatitis C virus NS3 ATPase/helicase: an ATP switch regulates the cooperativity among the different substrate binding sites.Biochemistry41: 10332-10342.
Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., and Bartenschlager, R. (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.Science285, 110-113.
Lucius, Al, Maluf NK, Fischer CJ, Lohman TM (2003) General methods for analysis of sequential “n-step” kinetic mechanisms: application to single turnover kinetics of helicase-catalyzed DNA unwinding.Biophys J85: 2224-39.
Martin, YC (1992) 3D Database Searching in Drug Design.J. Med. Chem. 35: 2145-2154.
Miranker, A and Karplus M (1991) Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method.Proteins: Structure. Function and Genetics11: 29-34.
Morris, PD, AK Byrd, AJ Tackett, CE Cameron, P Tanega, R Ott, E Fanning, and KD Raney (2002) Hepatitis C virus NS3 and simian virus 40 T antigen helicases displace streptavidin from 5′-biotinylated oligonucleotides but not from 3′-biotinylated oligonucleotides: evidence for directional bias in translocation on single-stranded DNA.Biochemistry41:2372-2378.
Mottola, G, Cardinali G, Ceccacci A, Trozzi C, Bartholomew L, Torrisi MR, Pedrazzini E, Bonatti S, Migliaccio G (2002) Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons.Virology293: 31-43.
Navia, MA and Murcko MA (1992) The Use of Structural Information in Drug Design.Current Opinions in Structural Biology2: 202-210.
Ng, P., Parks, R.J., and Graham, F.L. (2002) Preparation of helper-dependent adenoviral vectors, pp. 371-388 inGene Therapy Protocols, J.R. Morgan ed., Humana Press, Totowa, NJ.
Pang, PS, Jankowsky E, Planet PJ, Pyle AM (2002) The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding.EMBO J21: 1168-1176.
Piccininni, S., Varaklioti, A., Nardelli, M., Dave, B., Raney, K. D., and McCarthy, J. E. (2002) Modulation of the hepatitis C virus RNA-dependent RNA polymerase activity by the non-structural (NS) 3 helicase and the N
Cameron Craig E.
Dave Bhuvanesh
Jennings Thomas A.
Lu Jeff Zhiqiang
Mackintosh Samuel G.
Boesen Agnieszka
Campell Bruce
McTarish Hugh
The Board of Trustees of the University of Arkansas
LandOfFree
Compounds and methods for inhibiting hepatitis C virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for inhibiting hepatitis C virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for inhibiting hepatitis C virus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4026959